1. The latest on the AbbVie-Allergan tie-up — Patience needed for US biosimilar market — Medtech salary survey data — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Dealing with a potential legal issue at work?Ask an Employment Attorney -- a chance to discuss employment-related legal issues with a practicing attorney with over 20 years in employment law experience.
    Dismiss Notice

It's About TIme

Discussion in 'BioDelivery Sciences' started by anonymous, Mar 13, 2017 at 11:58 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    This company has 2 good products...it's about time it had a Cafe Pharma board
     

  2. anonymous

    anonymous Guest

    Bunavail must be inching closer to 1.0 MS, it's a CP requirement
     
  3. anonymous

    anonymous Guest

    How exactly is belbuca a good product?
     
  4. anonymous

    anonymous Guest

    C-3. More dose flexibility than Butrans. Works well for pain with less risk of overdose/addiction.
     
  5. anonymous

    anonymous Guest

    If it was such a great product Endo would have kept promoting it since Opana is going generic...moot point as it laid off pain team.
    Look at pain market...all is in a decline and most managedcare is paying for generic 1st...copay cards are going to get you in trouble with opioids
     
  6. anonymous

    anonymous Guest

    Yeah sure, try and convince doctors of that.
     
  7. anonymous

    anonymous Guest

    There are plenty of data to support these claims. Docs know it...but patients still clamor for their Oxys